Results 261 to 270 of about 410,880 (314)
Some of the next articles are maybe not open access.
Advances in Radiotherapy for Breast Cancer
Surgical Oncology Clinics of North America, 2023Breast cancer is the most prevalent cancer in women, and the second leading cause of cancer death in women in the United States. Radiation therapy is an important component in the multimodal management of breast cancer, including early stage and locally advanced breast cancers, as well as metastatic cases.
Rituraj, Upadhyay, Jose G, Bazan
openaire +2 more sources
The Treatment of Advanced Breast Cancer
The American Journal of Nursing, 1962of reigning supreme. In women throughout the United States, the breast is the most frequent single organ site of malignancy. Breast cancer is the leading cause of death of women in the prime of life, between 40 and 60 years of age. The incidence of this disease is incredibly high and shows no sign of declining.
openaire +2 more sources
PROGESTAGENS AND ADVANCED BREAST CANCER
The Lancet, 1971Abstract An interim analysis of the clinical responses in a controlled trial of œstrogens, an androgen, or a progestagen in the treatment of advanced breast cancer suggests that the progestagen used (17α-hydroxyprogesterone caproate 250 mg. intramuscularly three times a week) has no place in the management of generalised disease.
V, Jones +7 more
openaire +2 more sources
Olaparib for Advanced Breast Cancer
Future Oncology, 2020Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared with chemotherapy of physician choice.
Gaia, Griguolo +4 more
openaire +2 more sources
Management of Advanced Breast Cancer
Hormone Research, 2008The systemic treatment of advanced breast cancer is not curative in intent but steady progress is being made which should lessen the morbidity from metastatic disease. Reference has been made to relevant posters presented at the International Symposium on Endocrine Therapy.
openaire +2 more sources
Locally advanced breast cancer
Current Treatment Options in Oncology, 2000Over the past 20 years, the prognosis for women diagnosed with locally advanced breast cancer (LABC; clinical stages IIB through IIIB) has improved significantly with recognition of the efficacy of multimodal therapy for reducing both local and distant recurrences, even in patients with inflammatory breast cancer (IBC).
openaire +2 more sources
The control of advanced breast cancer
The American Journal of Surgery, 1963Abstract The control of breast cancer is now a three stage process. The initial surgical attack, irradiation therapy and chemotherapy. All must be employed. The consideration of various hormonal therapies and chemotherapies requires a thorough knowledge of the effectiveness of each individual therapy.
openaire +2 more sources
Trilostane in advanced breast cancer
Expert Opinion on Pharmacotherapy, 2006Antiestrogens, principally tamoxifen, and aromatase inhibitors have been used as the first- and second-line therapy in patients with advanced postmenopausal breast cancer for many years. However, some patients acquire resistance to these treatments and, at present, further endocrine treatment is achieved by merely substituting the current medication ...
John R, Puddefoot +2 more
openaire +2 more sources
Hypophysectomy in advanced breast cancer
The American Journal of Surgery, 1965THERE is undisputed evidence that the administration of steroid hormones or deprivation of hormone-producing tissues favorably modifies the anticipated behavior of advanced breast cancer. Extensive reviews have demonstrated the improvement that may be attained in selected patients after castration or adrenalectomy and the administration of estrogenic ...
B J, KENNEDY, L, FRENCH
openaire +2 more sources
Gemcitabine in advanced breast cancer
Anti-Cancer Drugs, 1995The experience with single-agent gemcitabine in advanced or metastatic breast cancer is reviewed. In all studies, gemcitabine was administered as a 30 min intravenous infusion in cycles once a week for 3 weeks followed by 1 week of rest. In the first European study (gemcitabine 800 mg/m2/week), of 40 evaluable patients, 14 were chemo-naive, 7 had ...
openaire +2 more sources